These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Non-alcoholic steatohepatitis in children. Nanda K Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336 [TBL] [Abstract][Full Text] [Related]
28. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Zheng H; Li S; Ma L; Cheng L; Deng C; Chen Z; Xie C; Xiang M; Jiang W; Chen L Eur J Pharmacol; 2011 Jun; 659(2-3):244-51. PubMed ID: 21463618 [TBL] [Abstract][Full Text] [Related]
31. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Ahmed MH; Byrne CD Drug Discov Today; 2007 Sep; 12(17-18):740-7. PubMed ID: 17826687 [TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Lebovics E; Rubin J Diabetes Metab Res Rev; 2011 Jul; 27(5):419-24. PubMed ID: 21425426 [TBL] [Abstract][Full Text] [Related]
33. [Therapeuric aspects of NAFLD. A literature review]. Tapia NC; Avila FI; Leiva JG; Ramos MH; Avila JF; Uribe M Rev Gastroenterol Mex; 2006; 71(4):487-95. PubMed ID: 17542283 [TBL] [Abstract][Full Text] [Related]
34. The treatment of NAFLD. Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594 [TBL] [Abstract][Full Text] [Related]
35. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Cheung O; Sanyal AJ Semin Liver Dis; 2008 Nov; 28(4):351-9. PubMed ID: 18956291 [TBL] [Abstract][Full Text] [Related]
36. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Federico A; Trappoliere M; Loguercio C Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661 [TBL] [Abstract][Full Text] [Related]
37. The epidemiology of nonalcoholic fatty liver disease in adults. Clark JM J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768 [TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for non-alcoholic steatohepatitis. Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366 [TBL] [Abstract][Full Text] [Related]
39. Current treatment of non-alcoholic fatty liver disease. Ahmed MH; Byrne CD Diabetes Obes Metab; 2009 Mar; 11(3):188-95. PubMed ID: 18564173 [TBL] [Abstract][Full Text] [Related]
40. The clinical aspects of non-alcoholic fatty liver disease. Björnsson E Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]